Cancer Therapy News and Research

RSS

Patients with plantar fasciitis experience less pain and improved QOL after standard radiation therapy

Patients with plantar fasciitis (painful bone heel spur) experience significantly less pain and improved quality of life following a standard dose of external beam radiation therapy, a common cancer treatment similar to receiving an X-ray, according to a randomized, cooperative group study that was published online July 25, 2012, in the International Journal of Radiation, Oncology, Biology, Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

30 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer from the stressful treatment which can be harmful to the developing brain. The most common childhood brain tumors are medulloblastoma and pylocytic astrocytoma.

27 Jul 2012

Study investigates molecular markers in drug-resistant ovarian cancer

A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of molecular markers in drug-resistant ovarian cancer with a view to improving clinical treatment.

27 Jul 2012

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer.

26 Jul 2012

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Constant pain after breast cancer surgery ‘more taxing’

Women who experience chronic pain after treatment for breast cancer are not significantly more anxious or depressed than women without pain, find researchers.

25 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Longer looks: Physicians and assisted suicide; Avoid getting sick in July

Peggy Sutherland was ready to die. The morphine oozing from a pump in her spine was no match for the pain of lung cancer, which had evaded treatment and invaded her ribs. … Sutherland, 68, decided to use Oregon's "Death With Dignity Act," which allows terminally-ill residents to end their lives after a 15-day requisite waiting period by self-administering a lethal prescription drug. ... But not all doctors are on board with the law.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

18 Jul 2012

Prostate cancer treatment regrets linked to comorbidity

Men with cardiovascular disease are significantly more likely to regret their prostate cancer treatment choice than men without this comorbidity and have an increased risk for adverse effects, US researchers warn.

16 Jul 2012

Study details how resistance to targeted drug therapy emerges in colorectal cancers

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

12 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

DRCRF names 21 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 21 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

11 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

Colon cancer cells use clever trick to migrate: Study

How does a tumor cell set up a signaling pathway in order to metastasize? Scientists at Technische Universit-t M-nchen's (TUM) Klinikum rechts der Isar and Helmholtz Zentrum M-nchen have made a significant discovery in this area by studying colon cancer.

11 Jul 2012

Protein interactions outside breast cancer cells can permanently stop proliferation

Protein interactions outside breast cancer cells can send signals to the cancer cells to permanently stop proliferating, a new study showed in the School of Medicine at The University of Texas Health Science Center San Antonio.

10 Jul 2012

Cancer Therapy News and Research

Patients with plantar fasciitis experience less pain and improved QOL after standard radiation therapy

Potential biomarker to predict lung cancer patients' response to chemotherapy

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Study investigates molecular markers in drug-resistant ovarian cancer

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Constant pain after breast cancer surgery ‘more taxing’

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Longer looks: Physicians and assisted suicide; Avoid getting sick in July

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

Prostate cancer treatment regrets linked to comorbidity

Study details how resistance to targeted drug therapy emerges in colorectal cancers

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

DRCRF names 21 new Damon Runyon Fellows

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Colon cancer cells use clever trick to migrate: Study

Protein interactions outside breast cancer cells can permanently stop proliferation

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News